Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in two fireside chats, Baird's 2021 Global Healthcare Conference, September 14-15 and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20-23, 2021. Both conferences will be held virtually.
During the fireside chats, Cue Biopharma will provide a data update highlighting its lead clinical program, CUE-101, representative of the IL-2 based CUE-100 series for the treatment of second line and beyond patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also focus on the Company’s latest developments and pipeline progress.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
About Baird's 2021 Global Healthcare Conference
About Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
About Cue Biopharma
Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
Brunch Served in ITEXPO #TECHSUPERSHOW Expo Hall
Mobile Edge Compute: Quick and Smart
Orchestration Getting to the Single Pane of Glass